Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,500 shares of the stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $22.18, for a total value of $277,250.00. Following the completion of the transaction, the chief executive officer now owns 952,892 shares in the company, valued at approximately $21,135,144.56. The trade was a 1.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Samuel Kintz also recently made the following trade(s):

• On Tuesday, June 3rd, Samuel Kintz sold 7,500 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.05, for a total value of $150,375.00.
• On Monday, May 19th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.49, for a total transaction of $82,450.00.
• On Thursday, May 1st, Samuel Kintz sold 5,330 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.08, for a total transaction of $107,026.40.
• On Thursday, April 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.42, for a total transaction of $82,100.00.

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock opened at $21.57 on Friday. The firm’s fifty day simple moving average is $18.65 and its 200-day simple moving average is $20.61. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -11.23 and a beta of 0.79.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). Analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

Hedge funds have recently made changes to their positions in the business. FMR LLC increased its position in Enliven Therapeutics by 3.2% in the 4th quarter. FMR LLC now owns 6,495,871 shares of the company’s stock valued at $146,157,000 after acquiring an additional 199,692 shares during the period. Polar Capital Holdings Plc grew its stake in shares of Enliven Therapeutics by 267.6% in the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock valued at $53,768,000 after purchasing an additional 1,739,668 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Enliven Therapeutics by 2.9% in the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company’s stock valued at $44,452,000 after purchasing an additional 55,283 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Enliven Therapeutics by 27.9% in the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company’s stock valued at $30,001,000 after purchasing an additional 290,153 shares during the period. Finally, Pictet Asset Management Holding SA raised its stake in shares of Enliven Therapeutics by 16.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company’s stock worth $21,877,000 after purchasing an additional 135,969 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ELVN shares. HC Wainwright lifted their price target on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, May 15th. Robert W. Baird upped their price objective on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday. The Goldman Sachs Group started coverage on Enliven Therapeutics in a research report on Monday. They set a “buy” rating and a $37.00 target price on the stock. Finally, Jones Trading decreased their target price on Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating for the company in a research report on Friday, May 16th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Enliven Therapeutics currently has an average rating of “Buy” and an average price target of $39.60.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.